Fate therapeutics to present at upcoming march investor conferences

San diego, march 01, 2024 (globe newswire) -- fate therapeutics, inc. (the “company” or “fate therapeutics”) (nasdaq: fate), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (ipsc)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the company will participate in the following upcoming investor conferences:
FATE Ratings Summary
FATE Quant Ranking